Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

November 16, 2018

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Stomach CancerStomach NeoplasmGastric CancerGastroesophageal Junction Adenocarcinoma
Interventions
DRUG

Ramucirumab

IV ramucirumab at 8 mg/kg on D1 and D15

DRUG

Paclitaxel

IV paclitaxel at 80 mg/m² on D1, D8 and D15

Trial Locations (38)

Unknown

CH -, Abbeville

CH - Albi, Albi

PRIVEE - L'Europe, Amiens

CAC - ICO Site Paul Papin, Angers

Privee - Hopital Prive, Antony

Ch - Victor Dupouy, Argenteuil

Ch - Metz Thionville Mercy, Ars-Laquenexy

Ch - Ght Unyon Auxerre, Auxerre

Privee - Institut Du Cancer Avignon Provence, Avignon

Ch - Cote Basque, Bayonne

Ch - Beauvais Ch, Beauvais

Chu - Jean Minjoz, Besançon

Privee - Tivoli, Bordeaux

PRIVEE - Polyclinique Saint Privat, Boujan-sur-Libron

Ch - Duchenne, Boulogne-sur-Mer

Ch - Pierre Oudot, Bourgoin

Privee - Pasteur Lanroze, Brest

Cac - François Baclesse, Caen

Chu - Côte de Nacre, Caen

Ch - Jean Rougier, Cahors

Privee - Infirmerie Protestante, Caluire-et-Cuire

CH -, Carcassonne

Ch - Castres Mazamet Chi, Castres

Prive - Médipole de Savoie, Challes-les-Eaux

Prive - Sainte Marie, Chalon-sur-Saône

CH -, Cholet

Ch - Hopitaux Civils de Colmar, Colmar

Hopitaux civils de Colmar, Colmar

Chu - Louis Mourier, Colombes

Prive - Saint Côme, Compiègne

Prive - Cédres, Cornebarrieu

Chu - Henri Mondor, Créteil

Prive - Centre Leonard de Vinci, Dechy

Cac - Gf Leclerc, Dijon

Chu - Francois Mitterrand, Dijon

CH -, Dunkirk

CHI - Elbeuf Louviers Val de Reuil, Elbeuf

Clinique privée - CENTRE CARIO, Plérin

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Federation Francophone de Cancerologie Digestive

OTHER

NCT03760822 - Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients | Biotech Hunter | Biotech Hunter